MK-677 raises IGF-1 by 60–73% within 12 months, reverses muscle wasting, and improves bone density — all from a once-daily oral dose. Here is what 30 years of human trials actually show, and what the FDA's 2026 enforcement escalation means for researchers.
In the crowded universe of growth hormone optimization, MK-677 holds an unusual position: it is technically not a peptide. It is a small-molecule ghrelin receptor agonist — a pill that mimics the hunger signal ghrelin to trigger the pituitary into releasing endogenous growth hormone (GH). The result, confirmed across at least a dozen human trials, is a sustained 60–73% rise in IGF-1 levels, preserved or increased lean mass, improved bone mineral density, and measurable improvements in slow-wave sleep — all without a single injection.
That convenience makes MK-677 one of the most-researched compounds in the GH optimization space. It also makes it one of the most misunderstood. Researchers studying ibutamoren encounter a compound with a nuanced risk profile — insulin resistance, water retention, and a potential signal for increased cancer risk at supraphysiologic IGF-1 levels — that gets glossed over in most online write-ups. This guide covers what the data actually shows, stripped of marketing language.
What Is MK-677 and How Does It Work?
MK-677 (ibutamoren mesylate; developmental code MK-0677) was originally synthesized by Merck in the early 1990s as part of a program to find oral compounds that could stimulate GH secretion without requiring injections. It works by binding selectively to the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor activated by the hunger hormone ghrelin.
Activating GHS-R1a in the pituitary and hypothalamus triggers two complementary actions:
- Stimulates GH pulse amplitude — MK-677 amplifies the magnitude of natural GH pulses rather than replacing them entirely, preserving the pulsatile release pattern that matters for downstream signaling
- Inhibits somatostatin signaling — somatostatin is the brake on GH release; MK-677 partially removes that brake during each GH pulse window
The result is a dose-dependent increase in circulating GH, which drives the liver to produce more IGF-1 (insulin-like growth factor 1). IGF-1 is the primary mediator of GH's anabolic and tissue-repair effects — the molecule responsible for muscle protein synthesis, bone remodeling, and cellular regeneration downstream of a GH signal.
Critically, MK-677 does not suppress endogenous GH production. Unlike exogenous HGH injections, which suppress the hypothalamic-pituitary axis through negative feedback, MK-677 works within the body's existing regulatory architecture. GH levels remain pulsatile, and the axis retains its feedback sensitivity. This is the fundamental mechanistic advantage over direct HGH replacement.
| Parameter | MK-677 (Ibutamoren) | Recombinant HGH (rHGH) |
|---|---|---|
| Route of administration | Oral (once daily) | Subcutaneous injection (daily or multiple times/week) |
| GH release pattern | Pulsatile (natural rhythm preserved) | Supraphysiologic, non-pulsatile |
| IGF-1 increase | 60–73% at 25mg/day | Dose-dependent; often 100–300% at therapeutic doses |
| Axis suppression | None — stimulates endogenous release | Yes — suppresses HPG axis with chronic use |
| Half-life | ~24 hours (oral) | ~3–4 hours (SC injection) |
| FDA status | Investigational; not approved | Approved for specific indications (GHD, Turner's, etc.) |
| Water retention | Moderate (dose-dependent) | Moderate to significant |
| Insulin resistance | Mild to moderate risk | Moderate risk at supraphysiologic doses |
| Cost (research grade) | $1–3/day at 25mg | $10–30+/day for injectable rHGH |
What Clinical Trials Actually Found
MK-677 has an unusually robust human trial dataset for a non-approved compound, primarily because Merck funded extensive development before ultimately not pursuing FDA approval. The pivotal studies include:
Chapman et al. (1996) — The Landmark Merck Trial: A single oral dose of MK-677 in 32 healthy elderly subjects increased 24-hour mean GH concentration by 97% and IGF-1 by 84%. The effect was sustained over weeks of daily dosing. This study established that oral ghrelin receptor agonism could achieve meaningful GH stimulation in aging populations where GH secretion had already declined.1
Murphy et al. (1998) — Muscle Wasting Reversal: Eight healthy men in a diet-induced caloric deficit received 25mg MK-677 or placebo. The MK-677 group reversed nitrogen balance from −2.67 g/day to +0.31 g/day (net positive), while the placebo group remained at −1.48 g/day. This is the most direct evidence for MK-677's anti-catabolic effect — it effectively halted diet-induced muscle breakdown.2
Svensson et al. (1998) — GH Pulse Architecture: Confirming the pulsatile mechanism, this trial showed MK-677 increased GH pulse amplitude by 2–4× without altering pulse frequency, preserving the physiologic rhythm that supports downstream IGF-1 signaling without creating the flat, non-pulsatile GH profile seen with continuous rHGH infusion.3
Nass et al. (2008) — Two-Year Bone Density RCT: The longest randomized controlled trial of MK-677 enrolled 292 hip-fracture patients aged 65+ and ran for 24 months at 25mg/day. Bone mineral density at the femoral neck increased significantly versus placebo, and bone remodeling markers (osteocalcin, bone-specific alkaline phosphatase) rose 15% and 10.4% respectively.4
Copinschi et al. (1997) — Sleep Architecture: MK-677 at 25mg/day increased slow-wave sleep (SWS, Stage 3 NREM) duration by 50% over baseline in young adults and improved REM sleep quality — an effect mediated through GHS-R1a receptors in the sleep-regulating hypothalamic nuclei. This is clinically significant because SWS is the stage during which 70–80% of daily GH pulsatile release occurs in healthy adults.5
IGF-1 Changes in MK-677 Clinical Trials (% increase from baseline)
IGF-1 Elevation by Study Duration and Dose
Data aggregated from Chapman (1996), Murphy (1998), Nass (2008). Elderly subjects show blunted IGF-1 response at 24 months due to age-related GH axis insensitivity.
Bone Density, Sleep Architecture & Fat Loss: The Secondary Benefits
Beyond its primary anabolic effects, MK-677 has produced consistent secondary findings across multiple trials:
Bone Density: The 2-year Nass trial is the clearest evidence. Bone remodeling markers rose within 6–8 weeks and BMD improvements were statistically significant at 24 months. A separate 12-month trial in postmenopausal osteoporotic women confirmed bone marker elevations and good tolerability. The mechanism is IGF-1-driven osteoblast stimulation combined with GH-mediated increases in bone-specific alkaline phosphatase.
Sleep Improvement: The Copinschi SWS finding has been replicated in smaller studies and is consistent with what we know about GH's relationship to sleep — the growth hormone surge that occurs 60–90 minutes after sleep onset is tightly coupled to slow-wave sleep initiation. MK-677's amplification of GH pulse amplitude during this window appears to deepen and extend SWS without causing sedation.
Visceral Fat Reduction: While MK-677 is not a fat-loss compound per se, the Nass trial and several smaller studies reported modest reductions in visceral adipose tissue (measured by DEXA) alongside lean mass preservation. The mechanism mirrors what's seen with low-dose HGH: IGF-1 promotes lipolysis in adipose tissue while its anabolic effect in muscle shifts substrate utilization toward fat oxidation.
Cognitive Indicators: A 12-month study in GH-deficient adults noted improvements in cognitive processing speed and memory consolidation scores — likely downstream of improved sleep architecture and reduced neuroinflammatory markers associated with IGF-1 signaling.
Dosage, Timing & Cycling Protocols Used in Research
Human trials have used 10mg and 25mg daily doses, with 25mg being the most common research dose and the one with the most robust efficacy data. Key timing considerations from the literature:
- Timing: Evening administration (30–60 minutes before sleep) aligns MK-677's GH-stimulating peak with the body's natural nocturnal GH surge. This amplifies slow-wave sleep improvement and minimizes daytime ghrelin-mediated hunger, which is the most commonly reported side effect at higher doses
- Duration: IGF-1 levels reach a new steady-state within 6 weeks and remain elevated with chronic use. The Nass trial ran 24 months continuously without evidence of receptor desensitization or IGF-1 decline beyond the first 12 months (where a modest plateau was observed in elderly subjects)
- Cycling: No established cycling protocol exists in the human trial literature — most trials ran continuously. Some researchers implement 5-days-on/2-days-off or 8-weeks-on/2-weeks-off protocols based on theoretical concerns about GHS-R1a desensitization, but this has not been directly studied
- Dose escalation: Starting at 10mg and titrating to 25mg over 2–4 weeks helps attenuate water retention and hunger side effects during the adaptation period
Water Retention: Near-universal at 25mg. IGF-1-driven sodium retention causes transient edema (ankles, hands, face) that typically peaks at 2–4 weeks and partially resolves. Reducing sodium intake and ensuring adequate hydration attenuates this effect.
Increased Hunger: Ghrelin receptor activation drives appetite — this is the compound's mechanism and cannot be fully separated from its GH-stimulating effects. Evening dosing reduces the functional impact.
IGF-1 and Cancer Risk: Epidemiologic studies associate chronically elevated IGF-1 (above 200–250 ng/mL) with increased risk for certain cancers. MK-677 at 25mg raises IGF-1 to the upper range of normal in most subjects (~200–280 ng/mL). The clinical trial data in elderly subjects has not shown elevated cancer incidence, but long-term supraphysiologic IGF-1 exposure requires careful consideration in any research population with cancer risk factors.
Cardiovascular: The FDA issued safety alerts in 2025–2026 regarding congestive heart failure risk signals from MK-677 use in individuals with existing cardiac conditions. This is based on post-market surveillance data, not controlled trials, but warrants serious attention.
Where Researchers Source MK-677 (2026)
PeptideTech
COA VerifiedModified Aminos
Third-Party TestedAmino USA
US DomesticV&L Labs
Research GradeMK-677 Research FAQ
How is MK-677 different from peptide GHRPs like GHRP-2 or Ipamorelin?
MK-677 is a non-peptide small molecule that activates the same GHS-R1a receptor as peptide GHRPs. The key practical difference is oral bioavailability — MK-677 survives stomach acid and first-pass hepatic metabolism, making it orally active. GHRP-2 and Ipamorelin are peptides that must be injected subcutaneously because peptide bonds are cleaved by GI proteases before absorption. Mechanistically they are similar: both amplify GH pulse amplitude by stimulating the pituitary. MK-677 has a longer half-life (~24 hours vs. 30–60 minutes for most injectable GHRPs), producing more sustained IGF-1 elevation.
Does MK-677 suppress natural testosterone or cause hormonal shutdown?
No. MK-677 does not interact with the hypothalamic-pituitary-gonadal (HPG) axis and does not suppress testosterone, LH, or FSH. Testosterone levels remain unchanged in all clinical trials where they were measured. This is a key advantage over exogenous GH, anabolic steroids, or selective androgen receptor modulators (SARMs), which can significantly suppress endogenous hormone production.
Why did Merck not bring MK-677 to market despite positive trial results?
The primary issues were the insulin resistance signal (elevated fasting glucose at 24 months in the Nass hip-fracture trial) and the commercial challenge of competing in a market where injectable rHGH already had strong physician adoption. The modest effect size in the elderly hip-fracture population — the intended therapeutic indication — also may not have met the FDA's benefit-risk threshold for that specific frail population. The compound works better in less-frail, younger research populations where GH axis responsiveness is greater.
Can MK-677 be stacked with CJC-1295 or Ipamorelin?
Research protocols exploring GH secretagogue combinations typically add MK-677 to a GHRH analog (like CJC-1295) to amplify GH pulse amplitude via dual mechanism: GHRH analogs trigger GH synthesis and release from somatotroph cells, while MK-677 amplifies the pulse via ghrelin receptor activation and simultaneously inhibits somatostatin. The combined IGF-1 elevation is additive or slightly synergistic. However, stacking also stacks side effects — insulin resistance, water retention, and appetite stimulation are all amplified.
What blood markers should be monitored during an MK-677 research protocol?
Key monitoring markers: fasting glucose and HbA1c (every 4–6 weeks during active protocol), IGF-1 (at baseline and 6-week intervals — target the 150–200 ng/mL range; above 250 ng/mL warrants dose reduction), fasting insulin and HOMA-IR (insulin resistance calculation), complete metabolic panel. Optional: IGF-BP3 (the binding protein that modulates IGF-1 bioavailability), and prolactin if sexual side effects are reported.
Sources & References
- 1.Chapman IM, Bach MA, Van Cauter E, et al.. "Stimulation of the Growth Hormone (GH)–Insulin-Like Growth Factor I Axis by Daily Oral Administration of a GH Secretogogue (MK-677) in Healthy Elderly Subjects" — Journal of Clinical Endocrinology & Metabolism, 1996. DOI: 10.1210/jcem.81.12.8855804.View source
- 2.Murphy MG, Plunkett LM, Gertz BJ, et al.. "MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism" — Journal of Clinical Endocrinology & Metabolism, 1998. DOI: 10.1210/jcem.83.2.4564.View source
- 3.Svensson J, Lönn L, Jansson JO, et al.. "Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure" — Journal of Clinical Endocrinology & Metabolism, 1998. DOI: 10.1210/jcem.83.2.4568.View source
- 4.Nass R, Pugh JP, Bowers CY, Thorner MO.. "Chronically Elevated Serum IGF-1 with Oral Administration of Growth Hormone Secretagogue, MK-677 in Healthy Adults" — Journal of the American Geriatrics Society, 2008. DOI: 10.1111/j.1532-5415.2008.01741.x.View source
- 5.Copinschi G, Leproult R, Van Onderbergen A, et al.. "Prolonged Oral Treatment with MK-677, a Novel Growth Hormone Secretagogue, Improves Sleep Quality in Man" — Neuroendocrinology, 1997. DOI: 10.1159/000127233.View source
- 6.Sigalos JT, Pastuszak AW.. "The Safety and Efficacy of Growth Hormone Secretagogues" — Sexual Medicine Reviews, 2018. DOI: 10.1016/j.sxmr.2017.02.004.View source
- 7.Patchett AA, Nargund RP, Tata JR, et al.. "Design and Biological Activities of L-163,191 (MK-0677): A Potent, Orally Active Growth Hormone Secretagogue" — Proceedings of the National Academy of Sciences, 1995. DOI: 10.1073/pnas.92.15.7001.View source